Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, August 9, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)   (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Company validates clinical development pathway via FDA Type B Meeting REHOVOT, Israel , and BRIDGEWATER, New Jersey , Aug. 3, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary
Toggle Summary Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
REHOVOT, Israel and BRIDGEWATER, N.J. , July 26, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
REHOVOT, Israel and BRIDGEWATER, New Jersey , June  29, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Present at the 2017 BIO International Convention
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 15, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 12, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 1, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Reports First Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , May 9, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (" Foamix Pharmaceuticals " or the "Company"), a clinical stage specialty pharmaceutical company focused on developing
Toggle Summary Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne
Pooled Analyses of Phase 3 Data Show Additional Statistically Significant Effects on Primary and Secondary Efficacy Endpoints Commencement of 3 rd Phase 3 Trial Planned mid 2017; Submittal of NDA Planned in H2-2018 Conference Call and Live Webcast with Slides at 8:30am ET Tomorrow , May 2nd
Toggle Summary Foamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference
REHOVOT, Israel , and BRIDGEWATER, New Jersey , April 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, May 10
REHOVOT, Israel , and BRIDGEWATER, New Jersey , April 26, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (" Foamix Pharmaceuticals "), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs
Toggle Summary Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
Conference Call and Webcast Today at 8:30 a.m. EDT REHOVOT, Israel , and BRIDGEWATER, New Jersey , March 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), today announced the topline results of its two Phase 3 clinical trials investigating FMX101, Trial 04 and Trial 05, in
Toggle Summary Foamix Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , March 8, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Present at the ROTH Capital Partners 29th Annual Growth Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , March 7, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , Feb. 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
REHOVOT, Israel , and BRIDGEWATER, New Jersey , Feb. 23, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Reports Year End 2016 Financial Results and Provides Business Update
Conference Call and Live Webcast Today at 8:30 a.m. Eastern Time REHOVOT, Israel , Feb. 22, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical
Toggle Summary Foamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22
REHOVOT, Israel , and BRIDGEWATER, New Jersey , Feb. 7, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
REHOVOT, Israel , and BRIDGEWATER, New Jersey , Feb. 6, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix to Host Key Opinion Leader Luncheon for Investors Focused on Dermatology, With a Focus on Acne and Rosacea
Meeting and Live Webcast on Friday, December 2, at 12pm Eastern Time REHOVOT, Israel , and BRIDGEWATER, New Jersey , Nov. 28, 2016  /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing